Verrica completes enrollment in COVE-2 Phase 3 trial; topline due Q1 2027
Verrica Pharmaceuticals said it completed enrollment in COVE-2, its first pivotal Phase 3 trial of YCANTH for common warts. Topline data are expected in Q1 2027.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.